MicroPort<sup>®</sup> Attends SOLACI 2015

Mexico City, Mexico - Shanghai MicroPort Medical (Group) Co ("MicroPort®") recently attended the Society of Latin American Cardiology Intervention 2015 ("SOLACI 2015") held from August 5 to August 7, and presented the independently designed third generation Firehawk® Rapamycin Target Eluting Coronary Stent System ("Firehawk®") with a satellite meeting.
 
MicroPort® invited Dr. Alfredo E. Rodriguze as the president of the satellite meeting themed "New Era for Target Eluting Stent - Firehawk® from Clinical Trials to Clinical Application." Dr. Renu Virmani, founder of CV Path Institute, Dr. Qiyi Luo, Chief Technology Officer of MicroPort®, and Dr. Yaojun Zhang from the First Hospital of Nanjing, were invited as guest speakers. Many experts participated in the satellite meeting.
 
During the meeting, Dr. Luo presented the new technical features of Firehawk® and Dr. Virmani focused on the pre-clinical study on Firehawk®. Dr. Yaojun Zhang released the latest clinical study results of Firehawk® Target series and introduced the Target All Comer – a large-scale randomized clinical trial that MicroPort® plans to carry out in the Europe – to participants. Meanwhile, Dr. Zhang shared the clinical experience in treating complex lesions with Firehawk® and spoke highly of its safety and efficacy.
 
During the interactive session, participants had a warm discussion on Firehawk®'s design, features, DAPT treatment time as well as the application of Firehawk® in complex diseases such as diabetes. In the end of the meeting, Dr. Rodriguez expressed his expectation to see Firehawk® launched in Argentina and other major South American countries soon, to provide solutions for more patients.
 
Aside from the satellite meeting, MicroPort®'s booth attracted a lot of attention from participants as well. Gary Minz, an international renowned intravascular ultrasound expert, also came to visit our booth and had in-depth discussion with Dr. Luo, Yinqing Lin, Vice President of MicroPort® International Business, and Ming Zheng, MicroPort® Senior Director of Medical Affairs. Through the meeting, MicroPort® presented the outstanding performance and growth potential of its innovative stent, paving the way for further opening up the Latin America market.